Redeye reinforces its positive view of CombinedX. The robust Q4 – with improving margins and underlying sales growth – completes a strong 2023 following up a softer IPO year. CombinedX’s focus on specialist companies working with one or a few software platforms has paid off, and management expects current market conditions to remain throughout 2024. We raise our forecasts and Base Case somewhat.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases